0.8725

0.24% 0.0013

Heron Therapeutics Inc (HRTX)

Overview News Price History Option Chain Financials Why HRTX Down? Discussions Forecast Stock Split

Heron Therapeutics Inc stock is traded at $0.8725, with a volume of 528.79K. It is up +0.24% in the last 24 hours and down -14.38% over the past month. Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Previous Close:

$0.8712

Open:

$0.88

24h Volume:

528.79K

Relative Volume:

0.24

Market Cap:

$165.15M

Revenue:

$154.90M

Net Income/Loss:

$-20.20M

P/E Ratio:

-7.2407

EPS:

-0.1205

Net Cash Flow:

$-27.91M

1W Performance:

+2.74%

1M Performance:

-14.38%

6M Performance:

-17.61%

1Y Performance:

-53.30%

1-Day Range:

$0.863

$0.8953

1-Week Range:

$0.8336

$0.8953

52-Week Range:

$0.7362

$2.30

Heron Therapeutics Inc Stock (HRTX) Company Profile

Name

Heron Therapeutics Inc

Sector

Healthcare (1107)

Industry

Biotechnology (619)

Phone

(858) 251-4400

Address

4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA

Employee

122

Twitter

Next Earnings Date

2026-05-11

Latest SEC Filings

HRTX's Discussions on Twitter

Compare HRTX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HRTX Heron Therapeutics Inc	0.8725	164.90M	154.90M	-20.20M	-27.91M	-0.1205
VRTX Vertex Pharmaceuticals Inc	434.64	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.92	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	811.41	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.09	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	155.84	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-09-25	Initiated	H.C. Wainwright	Buy
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-23-24	Initiated	CapitalOne	Overweight
Mar-13-24	Reiterated	Needham	Buy
May-27-20	Initiated	Guggenheim	Buy
Feb-20-20	Reiterated	Needham	Buy
Jan-16-19	Reiterated	Needham	Buy
Apr-05-18	Initiated	Evercore ISI	Outperform
Mar-19-18	Reiterated	Mizuho	Buy
Mar-01-18	Reiterated	Needham	Buy
Jan-03-18	Initiated	Leerink Partners	Outperform
Sep-27-17	Initiated	Northland Capital	Outperform
Feb-27-17	Initiated	Needham	Buy
Oct-26-16	Initiated	Aegis Capital	Buy
Sep-06-16	Resumed	Lake Street	Buy
May-03-16	Initiated	Cantor Fitzgerald	Buy
Dec-10-15	Initiated	Lake Street	Buy
Sep-23-15	Reiterated	Leerink Partners	Outperform
Sep-02-15	Initiated	BofA/Merrill	Buy
Aug-03-15	Reiterated	Brean Capital	Buy
Jun-30-15	Reiterated	JMP Securities	Mkt Outperform
Jun-19-15	Reiterated	Leerink Partners	Outperform
Aug-07-14	Initiated	Noble Financial	Buy

View All

Heron Therapeutics Inc Stock (HRTX) Latest News

May 19, 2026

Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright? - Insider Monkey

May 19, 2026

May 18, 2026

Heron Therapeutics (HRTX) price target decreased by 15.38% to 3.74 - MSN

May 18, 2026

May 16, 2026

Heron Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HRTX) 2026-05-16 - Seeking Alpha

May 16, 2026

May 15, 2026

Acute care revenue growth helps Heron (HRTX) reaffirm 2026 guidance despite Q1 sales decline - MSN

May 15, 2026

HRTX Stock Price, Quote & Chart | HERON THERAPEUTICS INC (NASDAQ:HRTX) - ChartMill

May 15, 2026

May 13, 2026

Heron outlines $173M-$183M 2026 net product sales outlook as it targets return to positive adjusted EBITDA - MSN

May 13, 2026

Adage Capital amendment shows 0% ownership in Heron Therapeutics (HRTX) - Stock Titan

May 13, 2026

Heron Therapeutics (HRTX) Quarterly Loss Revives Dilution Fears And Tests Profitability Narrative - Sahm

May 13, 2026

May 12, 2026

H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $4 - Moomoo

May 12, 2026

Heron Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo

May 12, 2026

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2026 Earnings Call Transcript - Insider Monkey

May 12, 2026

H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo

May 12, 2026

Needham Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $3 - Moomoo

May 12, 2026

H.C. Wainwright cuts Heron Therapeutics stock price target on weak Q1 results - Investing.com

May 12, 2026